Sp369
CHRONIC ABDOMINAL PAIN CASE PRESENTATION
Date
May 7, 2023
Explore related products in the following collection:
Society: AGA
Back by popular demand, the experts will share and debate the evidence and their approaches to chronic pain, defecatory disorders, dyspepsia. and gastroparesis. LIVE STREAM SESSION
Back by popular demand, the experts will share and debate the evidence and their approaches to chronic pain, defecatory disorders, dyspepsia. and gastroparesis. LIVE STREAM SESSION
Presenter
Mayo Clinic
Tracks
Related Products
A DOUBLE-BLIND PLACEBO CONTROLLED STUDY OF CLONIDINE AND COLESEVELAM FOR FECAL INCONTINENCE (FI)
Fecal incontinence is associated with substantial impacts on quality of life. Prevalence estimates range from 2% to as high as 20% based on the methodology used, and is likely underreported by patients. Prior studies have demonstrated inconsistent effects of body-mass index on fecal incontinence…
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
INTRODUCTION
SOCIETY: AGA
